Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: A meta-analysis

Meijiao He^{1#}, Yanxiang Zang^{1#}, Danghui Sun^{1#}, Jianqiang Li¹, Guangzhong Liu¹, Jing Shi¹, Yue Li^{1,2,3*}

Abstract

Objective: There exist conflicting data on the efficacy and safety of ticagrelor and clopidogrel in East Asian patients with acute coronary syndrome (ACS). We performed a meta-analysis to evaluate whether ticagrelor or clopidogrel produces better outcomes for East Asian patients with ACS. **Methods:** We searched for randomized controlled trials reporting associations between ticagrelor and clopidogrel in East Asian patients with acute coronary syndrome in PubMed, EMBASE, web of science and Cochrane central register of controlled trials. **Results:** Ten studies involving 3 715 participants were qualified for our analysis. The major adverse cardiovascular events (MACE) were significantly decreased in patients with ticagrelor treatment compared to those with clopidogrel (risk ratio [RR]: 0.61; 95% confidence interval [CI]: 0.38-0.98; $P = 0.042$). There was no significant difference in all-cause death (RR: 0.89; 95% CI: 0.61-1.29; $P = 0.540$), cardiovascular death (RR: 0.86; 95% CI: 0.58-1.27; $P = 0.451$), myocardial infarction (RR: 0.91; 95% CI: 0.65-1.27; $P = 0.575$) and stroke (RR: 0.77; 95% CI: 0.44-1.36; $P = 0.372$) between ticagrelor and clopidogrel. Ticagrelor was associated with a significantly higher risk of bleeding compared to clopidogrel (RR: 1.71; 95% CI: 1.37-2.13; $P = 0.000$). **Conclusion:** The present meta-analysis demonstrates that ticagrelor reduced the incidence of MACE in ACS patients from East Asia compared with clopidogrel. However, it increased the risk of bleeding.

Keywords

ticagrelor; clopidogrel; acute coronary syndrome; Eastern Asia; meta-analysis

Received 4 January 2021, accepted 6 May 2021

¹ Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin 150001, China.

² Institute of Metabolic Disease, Heilongjiang Academy of Medical Science, Harbin 150001, China

³ Heilongjiang Key Laboratory for Metabolic Disorder & Cancer Related Cardiovascular Diseases, Harbin 150081, China

*Corresponding author Yue Li, E-mail: ly99ly@vip.163.com

#These authors contributed equally to this work.

1 Introduction

Dual antiplatelet therapy (DAPT) with aspirin and P2Y₁₂ receptor inhibitor is the recommended antithrombotic therapy in patients with acute coronary syndrome (ACS)^[1]. Aspirin, an inhibitor of cyclooxygenase that prevents thromboxane A2 synthesis, is routinely prescribed for preventing thrombotic complications. Clopidogrel is a prodrug requiring the cytochrome P450 (CYP) enzymes for its biotransformation into an active thiol metabolite and the most widely prescribed anti-platelet drug for patients with ACS^[2-3]. Ticagrelor, a direct-acting, reversibly binding P2Y₁₂ receptor inhibitor, is a strongly recommended agent for patients with acute coronary syndrome (ACS)^[4-6]. In the PLATO trial^[7], ticagrelor was shown to be superior to clopidogrel in reducing the rate of death of vascular causes, myocardial

infarction, or stroke without an increase in the overall rate of major bleeding events. The PHILO trial^[8], which included 801 East Asian patients with ACS, reported that the rates of primary efficacy endpoints and major bleeding were higher in ticagrelor-treated patients than clopidogrel-treated patients. The controversies of the investigation results in terms of the risk profiles of thrombophilia and bleeding for ticagrelor versus clopidogrel exist in East Asian population, likely due to different genetic backgrounds. A meta-analysis^[9] enrolled 1 352 Eastern Asian patients with ACS from two randomized controlled trials (RCTs)^[8-10] demonstrated ticagrelor had no advantage in regard with its antithrombotic efficiency but increased the risk of major bleeding compared to clopidogrel. Another meta-analysis included 1 552 patients from 3 RCTs^[8,10,12] showed similar results. However, increasing evidence indicates that ticagrelor could provide a marginally or significantly

favorable antithrombotic efficacy in East Asian patients with ACS^[13-15]. Therefore, we performed the present meta-analysis to evaluate the efficacy and safety of ticagrelor and clopidogrel in Eastern Asian patients with ACS.

2 Methods

2.1 Search strategy

This meta-analysis was conducted by following the methods as previously described in detail^[16]. PubMed, EMBASE, web of science and Cochrane central register of controlled trials were independently searched by two investigators (YX Zang and DH Sun) until 1 November 2020. The following search terms or phrases were used in our study: 'clopidogrel' AND 'ticagrelor' AND ('acute coronary syndrome' OR 'unstable angina' OR 'myocardial infarction' OR 'percutaneous coronary intervention'). No language restrictions were applied.

2.2 Study selection

The studies had to fulfil the following criteria for their inclusion in our data analyses: (1) randomized controlled trials (RCT); (2) studies of East-Asian patients, which include Chinese, South Korean, Japanese and Mongolian patients; (3) the clinical trials that compared ticagrelor with clopidogrel; (4) articles with the available data for at least one of the following outcome measures: major adverse cardiovascular event (MACE), all-cause death, cardiovascular death, stroke, bleeding, major bleeding and minor bleeding; (5) the follow-up time was ≥ 6 months. The exclusion criteria included the following: repetitive publications; reviews; case reports; a short-time follow-up (less than 6 months).

2.3 Data extraction

Two investigators (YX Zang and DH Sun) independently screened and assessed the titles and abstracts for eligibility using the predefined inclusion criteria. Any disagreements and discrepancies in the analysis of the results were resolved by iteration and consensus. Data included the following information: name of the first author, publication year, study period, country, study design, sample size, clinical characteristics of the study population, duration of follow-up and results of the clinical outcomes. Quality assessment of the study was performed using the Cochrane Collaboration's risk of bias tool^[17], and we included all eligible RCTs regardless of their assessed quality.

2.4 Data synthesis

Analyses were performed using Stata version 12.0 statistical

software (StataCorp, USA). Heterogeneity of the pooled estimates was assessed using the I^2 statistic. The I^2 statistic describes the percentage of total variation across studies, which is due to heterogeneity; values of 25%, 50%, and 75% correspond to low, moderate, and high heterogeneity, respectively^[18-19]. All P -values were two-sided and less than 0.05 was considered statistically different.

3 Results

3.1 Study selection

A total of 3 861 literature citations were retrieved, including 126 potentially relevant studies as shown in Fig. 1. Of these, 126 potentially eligible articles were reviewed in full text. As a result, we included 10 articles in the meta-analysis, and the quality assessment of the study is shown in Fig. 2.

3.2 Study characteristics

Ten studies enrolled 3 715 participants matching the inclusion criteria including 1 855 participants that were designated to the ticagrelor treatment group and 1 860 participants that were designated to the clopidogrel treatment group^[8,10,12-14,20-24]. The ten studies were from countries including China, South Korea, and Japan. The baseline characteristics of the included studies and patients are shown in Table 1.

3.3 Meta-analysis

The rate of MACE (Fig. 3) with ticagrelor was dramatically lower than with clopidogrel (risk ratio [RR]: 0.61; 95% confidence interval [CI]: 0.38-0.98; $P = 0.042$). There was no significant difference in the all-cause death (RR: 0.89; 95% CI: 0.61-1.29; $P = 0.540$) (Fig. 4A), cardiovascular death (RR: 0.86; 95% CI: 0.58-1.27; $P = 0.451$) (Fig. 4B), myocardial infarction (RR: 0.91; 95% CI: 0.65-1.27; $P = 0.575$) (Fig. 4C) and stroke (RR: 0.77; 95% CI: 0.44-1.36; $P = 0.372$) (Fig. 4D) between ticagrelor treatment and clopidogrel treatment. Ticagrelor was associated with a significantly higher risk of bleeding (RR: 1.71; 95% CI: 1.37-2.13; $P = 0.000$) (Fig. 5A), which induced a significant increase in major bleeding (RR: 1.52; 95% CI: 1.11-2.09; $P = 0.010$) (Fig. 5B) and minor bleeding (RR: 1.73; 95% CI: 1.29-2.32; $P = 0.000$) (Fig. 5C), whereas clopidogrel was not.

3.4 Publication bias and sensitivity analysis

The publication bias of primary endpoint was high before sensitivity analysis or subgroup analysis (Egger's test bias $P > |t| = 0.012 < 0.05$). To explore the source of heterogeneity, the population of Chinese participants was analyzed as a subgroup,

Table 1 Baseline characteristics of included studies

References	Country	Follow-up (months)	Sample size (n)		Age (years)		Male (n)		Hypertension (%)		Diabetes (%)	
			Ticagrelor	Clopidogrel	Ticagrelor	Clopidogrel	Ticagrelor	Clopidogrel	Ticagrelor	Clopidogrel	Ticagrelor	Clopidogrel
Goto S <i>et al.</i> , 2015 ⁽⁷⁾	China, South Korea and Japan	12	401	400	67 ± 12	66 ± 11	306	307	76.1	72.5	38.4	31.0
Kang HJ <i>et al.</i> , 2015 ⁽⁹⁾	China and South Korea	12	278	273	NA	NA	NA	NA	NA	NA	NA	NA
Xia JG <i>et al.</i> , 2015 ⁽¹⁹⁾	China	6	48	48	53.7 ± 10.3	54.6 ± 9.8	36	38	62.5	64.6	50	45.8
Wang HD <i>et al.</i> , 2016 ⁽¹¹⁾	China	12	100	100	NA	NA	69	66	79	82	42	39
Tang XY <i>et al.</i> , 2016 ⁽²⁰⁾	China	6	200	200	64.36 ± 11.41	64.18 ± 11.09	142	146	61	58	29	21
Ren Q <i>et al.</i> , 2016 ⁽²¹⁾	China	12	149	151	56 ± 9.2	55 ± 8.0	102	106	NA	NA	NA	NA
Lu YJ <i>et al.</i> , 2016 ⁽²²⁾	China	12	95	108	59.25 ± 9.63	59.63 ± 9.88	52	60	34.7	38.9	25.3	29.6
Wu HB <i>et al.</i> , 2018 ⁽¹²⁾	China	12	124	120	58.976 ± 10.187	61.058 ± 11.600	98	94	51.6	57.5	25.8	20.8
Yang B <i>et al.</i> , 2018 ⁽¹³⁾	China	6	60	60	59.6 ± 15.7	58.7 ± 13.5	35	38	NA	NA	NA	NA
Park DW <i>et al.</i> , 2019 ⁽²³⁾	South Korea	12	400	400	62.5 ± 11.3	62.3 ± 11.5	297	302	55.8	48.2	29.0	25.0

Fig. 1 Flowchart of study screening

and the publication bias was revised (Egger's test bias $P > |t| = 0.812 > 0.05$). In addition, six trials were included in the Chinese subgroup, and there was no heterogeneity ($I^2 = 0\%$, $P = 0.873$). The fixed-effects model analysis showed a significant decrease of 62% in the incidence of MACE, from 12.33% (97/787) with clopidogrel to 4.77% (37/776) with ticagrelor ($RR: 0.38$; 95% $CI: 0.26-0.54$; $P < 0.001$) (Fig. 6).

4 Discussion

In the present meta-analysis, we included 3 715 participants from 10 randomized controlled trials for the evaluation of the efficacy and safety of ticagrelor and clopidogrel in Eastern Asian patients with ACS. The results revealed three important findings. First, the MACE was dramatically decreased in patients treated with ticagrelor compared to those with clopidogrel. Second, there was

no significant difference in the all-cause death, cardiovascular death, myocardial infarction and stroke between the two drug groups. Third, compared with clopidogrel, ticagrelor showed a remarkably higher risk of bleeding.

Ticagrelor is a direct-acting, reversibly binding $P2Y_{12}$ receptor antagonist for orally administration, which inhibits adenosine diphosphate-induced platelet aggregation. The PLATO trial, an international, multicenter, randomized, double-blind trial that enrolled 18 624 ACS patients, showed that ticagrelor significantly reduced the incidence of MACE (a composite of death from vascular causes, myocardial infarction or stroke) (569 [event rate at 360 days 9.0%] vs 668 [10.7%], hazard ratio 0.84, 95% CI 0.75–0.94; $P = 0.0025$)^[25]. However, two meta-analyses^[9,11] found that ticagrelor and clopidogrel displayed similar efficacies in ACS patients from East Asia. The present meta-analysis

Fig. 2 The quality assessment of the study

showed that the MACE was dramatically decreased in patients treated with ticagrelor compared to those with clopidogrel. Moreover, the present meta-analysis enrolled a greater number of trials and more Eastern Asian patients with ACS and provided more convincing results.

In the setting of ACS, the safety profile of P2Y₁₂ inhibitors, primarily the risk of major bleeding, is a concern among clinicians and patients. The PLATO trial found there was no difference between clopidogrel and ticagrelor in the rates of total major bleeding (691 [11.6%] vs 689 [11.5%], 0.99 [0.89-1.10]; $P = 0.880$). A recent SPACE-AA study^[26] which enrolled the patients from French national healthcare database demonstrated that ticagrelor had a significantly smaller risk of major bleeding than clopidogrel (163 [1.8%] vs 170 [1.8%], 1.02 [0.82-1.26]). However, our meta-analysis demonstrated that ticagrelor was associated with a higher risk of major bleeding relative to clopidogrel in East Asian patients with ACS. This

result is essentially the same as that reported by two published meta-analyses^[9,11]. A recent study carried out in New Zealand involving patients with acute myocardial infarction showed that the rate of minor bleeding one year post treatment was not significantly different in ticagrelor-treated patients from that in clopidogrel-treated patients (11.9% vs 11.2%, $P = 0.73$)^[27]. Our meta-analysis focused on East-Asian patients and found that ticagrelor had a remarkably higher risk in the minor bleeding than clopidogrel (RR: 1.73; 95%CI: 1.29-2.32; $P = 0.000$). This discrepancy could be explained by the racial variations in the bleeding risk. It was reported that the exposure rate to active metabolites was higher (nearly 20–30%) and pharmacodynamic reaction was stronger in Asian patients than in Caucasian following treatment with the same doses of P2Y₁₂ inhibitors^[28]. In addition, the exposures to ticagrelor and its active metabolite (AR-C124910XX) in Japanese volunteers tended to be 40% and 48% higher, respectively, than the white subjects, and even after being adjusted for body mass, the rates remained 14%

Fig. 3 Forest plots of major adverse cardiovascular events (MACE) between ticagrelor and clopidogrel

and 20% higher respectively^[29]. Consistently, Li *et al.*^[30] reported that compared with Caucasian counterparts, Chinese subjects tended to have approximately 40% higher concentrations of ticagrelor and AR-C124910XX Cmax and area under the plasma concentration-time curve of ticagrelor (90 mg twice daily). These studies suggested that East Asians are more susceptible to bleeding when treated with the standard-dose ticagrelor. Thus, to formulate appropriate dosages of anti-platelet agents to yield sufficient therapeutic efficacy and to minimize the risk of bleeding is crucial for ensuring successful and safe treatment of Eastern Asian patients with ACS.

In our previous study, we found that low-dose of ticagrelor elicited a greater platelet inhibitory effect than clopidogrel in Chinese patients with coronary artery disease (CAD)^[31-34]. In the PEGASUS-TIMI 54 trial^[35], ticagrelor at either 60 mg or 90 mg twice daily reduced the risk of cardiovascular death, myocardial infarction, or stroke in patients with myocardial infarction. These findings suggested an ideal balance in maintaining an adequate anti-platelet efficacy and minimizing the risk of adverse events is crucial to the successful treatment of CAD (in both East Asian and western patients). However, studies

on comparing low doses with standard doses of ticagrelor to evaluate the efficacy and safety in patients with CAD are still rather sparse. Larger-scale, well-designed studies with different doses of ticagrelor in patients with CAD are urgently needed.

5 Limitation

The limitations of this meta-analysis should be noted. First, the small number of enrolled patients from three Asian countries is the major limitation of the present analysis. Second, we only included PubMed, EMBASE, web of science and Cochrane central register of controlled trials for our search, and studies from other databases may have been missed out. Therefore, larger-scale studies that evaluate the efficacy and safety of ticagrelor and clopidogrel in Eastern Asian patients are warranted.

6 Conclusion

In conclusion, this meta-analysis demonstrated that ticagrelor yields a better efficacy in reducing the incidence of MACE in ACS patients from East Asia compared with clopidogrel. However, ticagrelor increases the risk of bleeding.

Fig. 4 Forest plots of A (All-cause death), B (Cardiovascular death), C (myocardial infarction), D (Stroke) between ticagrelor and clopidogrel

Fig. 5 Forest plots of A (Bleeding), B (Major bleeding), C (Minor bleeding) between ticagrelor and clopidogrel

MACE (Chinese population for subgroup)

Heterogeneity: chi-squared = 1.77 (d.f. = 5), $p = 0.873$

I-squared = 0.0%

Test of RR: $z = 5.32, p < 0.001$

RR: risk ratio

Fig. 6 Publication bias and sensitivity analysis. Forest plots of MACE in the Chinese population

Ethical approval and informed consent

This study was approved by the Research Ethics Committee of the First Affiliated Hospital of Harbin Medical University, and all participants signed informed consent form.

Author contributions

Yanxiang Zang and Danghui Sun designed the study and analyzed data. Meijiao He wrote the draft of the manuscript. All authors contributed to the interpretation of data, critical revision of the manuscript, and provided final approval of the submitted and published version.

Conflicts of interests

Yue Li is an Editorial Board Member of the journal. The article was subject to the journal's standard procedures, with peer review handled independently of this member and his research groups.

Acknowledgements

This work was supported by National Natural Science Foundation of China (81830012, 81900302, 82070336). We are grateful to TK Li for professional English editing of the manuscript.

References

- [1] Cuisset T, Verheugt F W A, Mauri L. Update on antithrombotic therapy after percutaneous coronary revascularization. *Lancet*, 2017; 390(10096): 810-820.
- [2] Gandhi S, Zile B, Tan M K, *et al.* Increased uptake of guideline-recommended oral antiplatelet therapy: insights from the Canadian acute coronary syndrome reflective. *Can J Cardiol*, 2014; 30(12): 1725-1731.
- [3] Karve A M, Seth M, Sharma M, *et al.* Contemporary use of ticagrelor in interventional practice (from blue cross blue shield of michigan cardiovascular consortium). *Am J Cardiol*, 2015; 115(11): 1502-1506.
- [4] Levine G N, Bates E R, Blankenship J C, *et al.* 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: An update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. *J Am Coll Cardiol*, 2016; 67(10): 1235-1250.
- [5] Authors/Task Force members, Windecker S, Kolh P, *et al.* 2014 ESC/

EACTS guidelines on myocardial revascularization: The task force on myocardial revascularization of the European Society Of Cardiology (ESC) and the European association for cardio-thoracic surgery (EACTS) Developed with the special contribution of the European association of percutaneous cardiovascular interventions (EAPCI). *Eur Heart J*, 2014; 35(37):2541-2619.

[6] 2012 Writing Committee Members, Jneid H, Anderson J L, *et al*. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American college of cardiology foundation/american heart association task force on practice guidelines. *Circulation*, 2012; 126(7): 875-910.

[7] Wallentin L, Becker R C, Budaj A, *et al*. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*, 2009; 361(11): 1045-1057.

[8] Goto S, Huang C H, Park S J, *et al*. Ticagrelor vs. Clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome-randomized, double-blind, phase III PHILO Study. *Circ J*, 2015; 79(11):2452-2460.

[9] Wu B, Lin H, Tobe R G, *et al*. Ticagrelor versus clopidogrel in East-Asian patients with acute coronary syndromes: a meta-analysis of randomized trials. *J Comp Eff Res*, 2018; 7(3): 281-291.

[10] Kang H J, Clare R M, Gao R, *et al*. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: a retrospective analysis from the platelet inhibition and patient outcomes (PLATO) Trial. *Am Heart J*, 2015; 169(6): 899-905.

[11] Misumida N, Aoi S, Kim S M, *et al*. Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: Systematic review and meta-analysis. *Cardiovasc Revasc Med*, 2018; 19(6): 689-694.

[12] Wang H, Wang X. Efficacy and safety outcomes of ticagrelor compared with clopidogrel in elderly Chinese patients with acute coronary syndrome. *Ther Clin Risk Manag*, 2016; 12: 1101-1105.

[13] Wu H B, Tian H P, Wang X C, *et al*. Clinical efficacy of ticagrelor in patients undergoing emergency intervention for acute myocardial infarction and its impact on platelet aggregation rate. *Am J Transl Res*, 2018; 10(7): 2175-2183.

[14] Yang B, Zheng C, Yu H, *et al*. Comparison of ticagrelor and clopidogrel for patients undergoing emergency percutaneous coronary intervention. *Iran J Public Health*, 2018; 47(7): 952-957.

[15] Gao C Z, Ma Q Q, Wu J, *et al*. Comparison of the effects of ticagrelor and clopidogrel on inflammatory factors, vascular endothelium functions and shortterm prognosis in patients with acute stsegment elevation myocardial infarction undergoing emergency percutaneous coronary intervention: a pilot study. *Cell Physiol Biochem*, 2018; 48(1): 385-396.

[16] Shamseer L, Moher D, Clarke M, *et al*. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*, 2015; 350: g7647.

[17] Higgins J P, Altman D G, Gøtzsche P C, *et al*. The cochrane collaboration's tool for assessing risk of bias in randomised trials. *BMJ*, 2011; 343: d5928.

[18] Huedo-Medina T B, Sánchez-Meca J, Marín-Martínez F, *et al*. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? *Psychol Methods*, 2006; 11(2): 193-206.

[19] Higgins J P, Thompson S G, Deeks J J, *et al*. Measuring inconsistency in meta-analyses. *BMJ*, 2003; 327(7414): 557-560.

[20] Xia J G, Qu Y, Hu S D, *et al*. Midterm follow-up outcomes of ticagrelor on acute ST segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. *Beijing Da Xue Xue Bao. Yi Xue Ban*, 2015; 47(3): 494-498.

[21] Tang X, Li R, Jing Q, *et al*. Assessment of ticagrelor versus clopidogrel treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. *J Cardiovasc Pharmacol*, 2016; 68(2): 115-120.

[22] Ren Q, Ren C, Liu X, *et al*. Ticagrelor vs. clopidogrel in non-ST-elevation acute coronary syndromes. *Herz*, 2016; 41(3): 246-249.

[23] Lu Y, Li Y, Yao R, *et al*. Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention. *Exp Ther Med*, 2016; 11(6): 2177-2184.

[24] Park D W, Kwon O, Jang J S, *et al*. Clinically significant bleeding with ticagrelor versus clopidogrel in Korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial. *Circulation*, 2019; 140(23): 1865-1877.

[25] Cannon C P, Harrington R A, James S, *et al*. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomized double-blind study. *The lancet*, 2010; 375(9711):283-293.

[26] Blin P, Dureau-Pournin C, Benichou J, *et al*. Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database. *Atherosclerosis*, 2018; 281(7): 98-106.

[27] Harding S A, Holley A, Wilkins B, *et al*. Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor? *Intern Med J*, 2017; 47(11): 1298-1305.

[28] Small D S, Payne C D, Kothare P, *et al*. Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. *Clin Ther*, 2010; 32(2): 365-379.

[29] Teng R, Butler K. Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers. *Int j Clin Pharmacol Ther*, 2014; 52(6): 478-491.

[30] Li H, Butler K, Yang L, *et al*. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: An open-label, sequential, two-cohort, single-centre study. *Clin Drug Invest*, 2012; 32(2): 87-97.

- [31] He M J, Liu B, Sun D H, *et al.* One-quarter standard-dose ticagrelor better than standard-dose clopidogrel in Chinese patients with stable coronary artery disease: A randomized, single-blind, crossover clinical study. *Int J Cardiol*, 2016; 215: 209-213.
- [32] He M, Li D, Zhang Y, *et al.* Effects of different doses of ticagrelor on platelet aggregation and endothelial function in diabetic patients with stable coronary artery disease. *Platelets*, 2019; 30(6): 752-761.
- [33] He M, Zhang Y, Yan W, *et al.* 60 mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: A randomized, single-blind, crossover study. *Thromb Res*, 2020; 190: 60-61.
- [34] Shi J, He M, Wang W, *et al.* Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR). *Platelets*, 2020; 23: 1-10.
- [35] Bonaca M P, Bhatt D L, Cohen M, *et al.* Long-term use of ticagrelor in patients with prior myocardial infarction. *N Engl J Med*, 2015; 372(19): 1791-1800.